Has COVID-19 changed the future of pharmaceutical regulation?


  • Harriet Edwards




COVID-19, SARS-CoV-2, AAV Vaccine, MHRA Conditional Approval, Advanced Therapy Medicinal Products, regenerative medicine, regulation, mRNA Vaccine, emergency use authorization


COVID-19, or SARS-CoV-2, has undoubtedly changed the world as we know it, affecting daily life, health, and economics to an unprecedented degree. Due to the widespread and devastating impact of this previously unknown virus, there has been a massive effort from the pharmaceutical industry to rapidly develop a vaccine to protect the population. As a consequence of the increasingly evolving threat of COVID-19, developers and regulators have had to respond accordingly, learning about the virus while attempting to develop and regulate treatments concurrently. As if this task was not complex enough, developers and regulators have had to face this challenge while simultaneously tackling arguably the largest widescale media attention and pressure that has ever been felt by the industry, with mainstream media, politicians, and the general public all having a vested interest in the development of the vaccines and an opinion on how they should be developed, distributed, and monitored. It is therefore a true testament to developers and regulators alike that many vaccines have already been authorized for use (or are about to be) in so many countries and territories across the world, in record time. However, this success brings many questions as to why other medicines have not been regulated at such speed before and whether the SARS-CoV-2 vaccines have received ‘special treatment’, with many posing the question: ‘are these vaccines actually safe?’. One thing that is clear, at least to the industry, is that the incredible flexibility, pragmatism, and creativity of developers and regulators in their approach to authorizing the vaccines has, unequivocally, been a main contributor to the rapid availability of these novel vaccines. This article aims to examine whether COVID-19 (SARS-CoV-2) has changed the future of regulation through identifying and discussing the notable regulatory milestones achieved over the course of the COVID-19 pandemic (to date), and critically analyzing the regulation of those successful vaccine candidates that have been authorized at the time of writing, while posing the ultimate question; has COVID-19 revolutionized the future of regulation of medicine development and authorization or are we simply responding to an unprecedented global pandemic?



UK Statutory Instruments. (2012). The Human Medicines Regulations 2012. (No.1916 Part 10). Retrieved February 15, 2021 from https://www.legislation.gov.uk/uksi/2012/1916/contents/made

Medicines & Healthcare products Regulatory Agency. (2020). Conditions of Authorisations for Pfizer/BioNTech COVID-19 vaccine. Retrieved February 15, 2021 from https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine

United States Food & Drug Administration. (2017, January). Emergency Use Authorization of Medical Products and Related Authorities. Retrieved February 15, 2021 from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities

COVID-19 Vaccine Tracker. (n.d.). Vaccines – COVID19 Vaccine Tracker. Retrieved February 15, 2021 from https://covid19.trackvaccines.org/vaccines/

United States Food & Drug Adminstration. (2021) Pfizer-BioNTech COVID-19 Vaccine. Retrieved February 15, 2021 https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine

European Medicines Agency. (2020). Comirnaty. Retrieved February 15, 2021 from https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

UK Department of Health and Social Care & Medicines & Healthcare products Regulatory Agency. (n.d.). Reg 174 Information for UK Healthcare Professionals. Retrieved February 15, 2021 from https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997050/Temporary_Authorisation_HCP_Information_BNT162_12_0_UK_clean.pdf

Townsen, K. & Stockton, L. L. P. (2021, January 11). The Lead COVID-19 Vaccine Candidates: Where We Are and What You Should Know. Retrieved February 15, 2021 from https://www.kilpatricktownsend.com/Blog/MEMO/2021/1/The-Lead-COVID-19-Vaccine-Candidates---Where-We-Are-and-What-You-Should-Know

Zimmer, C., Corum, J. & Wee, S. L. (2021). Coronavirus Vaccine Tracker. Retrieved February 15, 2021 from https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html



2021-07-14 — Updated on 2021-07-15




Review Articles

How to Cite

Has COVID-19 changed the future of pharmaceutical regulation?. (2021). Journal of Regulatory Science, 9(2), 1-8. https://doi.org/10.21423/JRS-V09I2EDWARDS (Original work published 2021)